Avience Biomedicals IPO Subscription Status Day 2: Issue Booked 18.98 Times as Retail, NII Demand Soars

Mumbai, June 19: Avience Biomedicals IPO continued to attract strong investor interest on the second day of bidding, with the issue subscribed 18.98 times as of 10:55 AM on June 19, 2026. Demand remained exceptionally strong from both retail and non-institutional investors, pushing the overall subscription sharply higher compared to the first day.

The ₹30.24 crore NSE SME issue opened for subscription on June 18, 2026, and will remain available for bidding until June 22, 2026. The company is offering shares at an issue price of ₹208 per share.

Avience Biomedicals IPO Subscription Status Today

According to exchange data available as of 10:55 AM on Day 2, the IPO received bids for 1,82,50,800 shares against 9,61,800 shares available for subscription, resulting in an overall subscription of 18.98 times.

Investor participation remained concentrated in the retail and NII categories, both of which were heavily oversubscribed within the first two days of bidding.

The category-wise subscription stood at:

• Retail Individual Investors: 26.27x
• NII Category: 27.09x
• bNII Portion: 26.91x
• sNII Portion: 27.45x
• QIB (Ex Anchor): 0.00x
• Overall Subscription: 18.98x

The IPO had received more than 12,100 applications at the time of the latest update.

Retail Investors Continue To Lead Demand

Retail investors remained highly active on Day 2.

The retail category was subscribed 26.27 times, receiving bids for 1,26,43,200 shares against 4,81,200 shares reserved for the segment.

The strong response suggests sustained interest from individual investors despite the issue already witnessing a healthy subscription on the opening day.

NII Portion Witnesses Heavy Oversubscription

The non-institutional investor category also recorded robust demand, with the segment subscribed 27.09 times.

The NII portion attracted bids for 56,07,600 shares against 2,07,000 shares on offer.

Within the category, the sNII portion was subscribed 27.45 times, while the bNII segment was booked 26.91 times, indicating broad-based participation from high-net-worth investors.

Subscription Jumps From Day 1 Levels

The IPO has seen a sharp increase in demand compared with the opening day.

On Day 1, the issue was subscribed 10.75 times, with the retail category booked 15.69 times and the NII portion subscribed 13.49 times.

By the second day, overall subscription had climbed to 18.98 times, highlighting accelerating investor interest as the issue moved closer to its closing date.

Avience Biomedicals IPO Details

Avience Biomedicals is looking to raise ₹30.24 crore through a book-built SME public issue.

The issue comprises:

• Fresh Issue: 13,71,600 equity shares aggregating ₹30.24 crore
• Offer For Sale: Nil

The company has fixed the issue price at ₹208 per share.

Key issue details include:

• Issue Size: ₹30.24 crore
• Issue Price: ₹208 per share
• Lot Size: 600 shares
• Minimum Retail Application: 1,200 shares
• Minimum Investment: ₹2,49,600
• IPO Closing Date: June 22, 2026
• Tentative Allotment Date: June 23, 2026
• Tentative Listing Date: June 25, 2026
• Listing Platform: NSE SME

Avience Biomedicals IPO Reservation Details

The net issue has been allocated across investor categories as follows:

• QIB Portion: 6,83,400 shares (49.83% of net issue)

• NII Portion: 2,07,000 shares (15.09% of net issue)

• Retail Portion: 4,81,200 shares (35.08% of net issue)

Additionally, 82,200 shares have been reserved for the market maker.

About Avience Biomedicals

Avience Biomedicals operates in the healthcare and biomedical products segment. The company focuses on providing healthcare solutions and serves customers across various medical and healthcare-related categories.

The IPO proceeds are expected to support the company’s growth plans and business expansion initiatives.

Conclusion

Avience Biomedicals IPO has emerged as one of the most strongly subscribed SME issues in the market this week, with demand nearing 19 times on Day 2. Strong participation from both retail and NII investors has driven the subscription numbers higher, while investors will now watch whether institutional demand joins the issue before bidding closes on June 22, 2026.

Source:

• https://www.chittorgarh.net/reports/anchor-investor/aviencebiomedicals_anchorallocationreport.pdf